Last reviewed · How we verify

NCT03525899

Macular Hole After Diabetic Vitrectomy

Completed Last updated 16 May 2018
What this trial tests

trial testing Pars plana vitrectomy in Proliferative Diabetic Retinopathy in 7 participants. Completed in 1 December 2017.

Timeline
1 November 2017
Primary endpoint
1 December 2017
1 December 2017

Quick facts

Lead sponsorNational Taiwan University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment7
Start date1 November 2017
Primary completion1 December 2017
Estimated completion1 December 2017
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

National Taiwan University Hospital

Who can join

Adults 18 to 80, any sex, with Proliferative Diabetic Retinopathy or Macular Holes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To present the clinical characteristics and rational treatment of macular hole (MH) after the diabetic vitrectomy (DV) in patients with proliferative diabetic retinopathy (PDR).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Pars plana vitrectomy

Trials testing the same drug.

Other recruiting trials for Proliferative Diabetic Retinopathy

Currently open trials in the same condition.

Other National Taiwan University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03525899.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing